You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameRescinnamine
Accession NumberDB01180  (APRD00112)
TypeSmall Molecule
GroupsApproved
DescriptionRescinnamine is an angiotensin-converting enzyme inhibitor used as an antihypertensive drug. It is an alkaloid obtained from Rauwolfia serpentina and other species of Rauwolfia. [Wikipedia]
Structure
Thumb
Synonyms
3,4,5-Trimethoxycinnamoyl methyl reserpate
Rescinnamine
Trimethoxy cinnamoyl reserpate de methyl
Tsuruselpi S
External Identifiers Not Available
Approved Prescription ProductsNot Available
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
Tsuruselpi SNot Available
Brand mixturesNot Available
SaltsNot Available
Categories
UNIIQ6W1F7DJ2D
CAS number24815-24-5
WeightAverage: 634.716
Monoisotopic: 634.289030952
Chemical FormulaC35H42N2O9
InChI KeyInChIKey=SZLZWPPUNLXJEA-QEGASFHISA-N
InChI
InChI=1S/C35H42N2O9/c1-40-21-8-9-22-23-11-12-37-18-20-15-29(46-30(38)10-7-19-13-27(41-2)33(43-4)28(14-19)42-3)34(44-5)31(35(39)45-6)24(20)17-26(37)32(23)36-25(22)16-21/h7-10,13-14,16,20,24,26,29,31,34,36H,11-12,15,17-18H2,1-6H3/b10-7+/t20-,24+,26-,29-,31+,34+/m1/s1
IUPAC Name
methyl (1R,15S,17R,18R,19S,20S)-6,18-dimethoxy-17-{[3-(3,4,5-trimethoxyphenyl)prop-2-enoyl]oxy}-3,13-diazapentacyclo[11.8.0.0²,¹⁰.0⁴,⁹.0¹⁵,²⁰]henicosa-2(10),4(9),5,7-tetraene-19-carboxylate
SMILES
[H][C@]12C[C@@H](OC(=O)C=CC3=CC(OC)=C(OC)C(OC)=C3)[[email protected]](OC)[C@@H](C(=O)OC)[C@@]1([H])C[C@@]1([H])N(CCC3=C1NC1=C3C=CC(OC)=C1)C2
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as yohimbine alkaloids. These are alkaloids containing the pentacyclic yohimban skeleton. The Yohimbinoid alkaloids contain a carbocyclic ring E arising through C-17 to C-18 bond formation in a corynantheine precursor.
KingdomOrganic compounds
Super ClassAlkaloids and derivatives
ClassYohimbine alkaloids
Sub ClassNot Available
Direct ParentYohimbine alkaloids
Alternative Parents
Substituents
  • Yohimbine
  • Corynanthean skeleton
  • Yohimbine alkaloid
  • Pyridoindole
  • Beta-carboline
  • Cinnamic acid ester
  • Coumaric acid or derivatives
  • Cinnamic acid or derivatives
  • Phenylpropene
  • Indole or derivatives
  • Indole
  • Methoxybenzene
  • Styrene
  • Phenol ether
  • Anisole
  • Aralkylamine
  • Fatty acid ester
  • Alkyl aryl ether
  • Fatty acyl
  • Benzenoid
  • Piperidine
  • Dicarboxylic acid or derivatives
  • Monocyclic benzene moiety
  • Heteroaromatic compound
  • Alpha,beta-unsaturated carboxylic ester
  • Enoate ester
  • Methyl ester
  • Pyrrole
  • Tertiary aliphatic amine
  • Tertiary amine
  • Carboxylic acid ester
  • Azacycle
  • Organoheterocyclic compound
  • Ether
  • Dialkyl ether
  • Carboxylic acid derivative
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Carbonyl group
  • Amine
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External DescriptorsNot Available
Pharmacology
IndicationFor the treatment of hypertension.
PharmacodynamicsUsed to treat hypertension. Rescinnamine inhibits angiotensin-converting enzyme. ACE is a peptidyl dipeptidase that catalyzes the conversion of angiotensin I to the vasoconstrictor substance, angiotensin II. Angiotensin II also stimulates aldosterone secretion by the adrenal cortex and general vasoconstriction, both of which lead to increases vascular resistance. By inhibiting angiotensin II, aldosterone reabsorption is decreased as well as vasoconstriction. This combined effect serves to decrease blood pressure.
Mechanism of actionRescinnamine Binds to and inhibits the angiotensin converting enzyme. Rescinnamine competes with angiotensin I for binding at the angiotensin-converting enzyme, blocking the conversion of angiotensin I to angiotensin II. Inhibition of ACE results in decreased plasma angiotensin II. As angiotensin II is a vasoconstrictor and a negative-feedback mediator for renin activity, lower concentrations result in a decrease in blood pressure and stimulation of baroreceptor reflex mechanisms, which leads to decreased vasopressor activity and to decreased aldosterone secretion.
Related Articles
AbsorptionNot Available
Volume of distributionNot Available
Protein bindingNot Available
MetabolismNot Available
Route of eliminationNot Available
Half lifeNot Available
ClearanceNot Available
ToxicityNot Available
Affected organisms
  • Humans and other mammals
Pathways
PathwayCategorySMPDB ID
Rescinnamine Action PathwayDrug actionSMP00155
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9604
Blood Brain Barrier+0.9248
Caco-2 permeable+0.6805
P-glycoprotein substrateSubstrate0.8163
P-glycoprotein inhibitor IInhibitor0.8826
P-glycoprotein inhibitor IINon-inhibitor0.6553
Renal organic cation transporterInhibitor0.5
CYP450 2C9 substrateNon-substrate0.8706
CYP450 2D6 substrateNon-substrate0.9064
CYP450 3A4 substrateSubstrate0.7223
CYP450 1A2 substrateInhibitor0.9107
CYP450 2C9 inhibitorNon-inhibitor0.9071
CYP450 2D6 inhibitorNon-inhibitor0.923
CYP450 2C19 inhibitorNon-inhibitor0.9144
CYP450 3A4 inhibitorNon-inhibitor0.8203
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.7162
Ames testNon AMES toxic0.9208
CarcinogenicityNon-carcinogens0.9453
BiodegradationNot ready biodegradable1.0
Rat acute toxicity2.8345 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.697
hERG inhibition (predictor II)Non-inhibitor0.678
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
PackagersNot Available
Dosage formsNot Available
PricesNot Available
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point238.5 °CPhysProp
logP3.5Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.00349 mg/mLALOGPS
logP4.48ALOGPS
logP4.07ChemAxon
logS-5.3ALOGPS
pKa (Strongest Acidic)16.29ChemAxon
pKa (Strongest Basic)7.56ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count8ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area117.78 Å2ChemAxon
Rotatable Bond Count11ChemAxon
Refractivity171.16 m3·mol-1ChemAxon
Polarizability69.65 Å3ChemAxon
Number of Rings6ChemAxon
Bioavailability0ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Download (13.2 KB)
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
References
Synthesis ReferenceNot Available
General ReferencesNot Available
External Links
ATC CodesC02AA01C02LA02C02LA52
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelNot Available
MSDSDownload (52.7 KB)
Interactions
Drug Interactions
Drug
7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE may increase the hypotensive activities of Rescinnamine.
AcebutololAcebutolol may increase the hypotensive activities of Rescinnamine.
AceclofenacThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Aceclofenac.
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Acetylsalicylic acid.
Acetylsalicylic acidAcetylsalicylic acid may decrease the antihypertensive activities of Rescinnamine.
AdapaleneThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Adapalene.
AlfuzosinAlfuzosin may increase the hypotensive activities of Rescinnamine.
AliskirenAliskiren may increase the hypotensive activities of Rescinnamine.
AllopurinolThe risk of a hypersensitivity reaction to Allopurinol is increased when it is combined with Rescinnamine.
AlogliptinThe risk or severity of adverse effects can be increased when Alogliptin is combined with Rescinnamine.
AlprenololAlprenolol may increase the hypotensive activities of Rescinnamine.
AmbrisentanRescinnamine may increase the hypotensive activities of Ambrisentan.
AmifostineRescinnamine may increase the hypotensive activities of Amifostine.
AmilorideAmiloride may increase the hyperkalemic activities of Rescinnamine.
Aminosalicylic AcidAminosalicylic Acid may decrease the antihypertensive activities of Rescinnamine.
AmlodipineAmlodipine may increase the hypotensive activities of Rescinnamine.
AntipyrineThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Antipyrine.
ApremilastThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Apremilast.
AprotininAprotinin may decrease the antihypertensive activities of Rescinnamine.
ArdeparinArdeparin may increase the hyperkalemic activities of Rescinnamine.
AtenololAtenolol may increase the hypotensive activities of Rescinnamine.
AtorvastatinThe risk or severity of adverse effects can be increased when Atorvastatin is combined with Rescinnamine.
AzapropazoneThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Azapropazone.
AzathioprineRescinnamine may increase the myelosuppressive activities of Azathioprine.
AzelastineThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Azelastine.
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Rescinnamine.
BalsalazideThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Balsalazide.
BemiparinBemiparin may increase the hyperkalemic activities of Rescinnamine.
BenazeprilBenazepril may increase the hypotensive activities of Rescinnamine.
BendroflumethiazideBendroflumethiazide may increase the hypotensive activities of Rescinnamine.
BenmoxinBenmoxin may increase the hypotensive activities of Rescinnamine.
BenoxaprofenThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Benoxaprofen.
BepridilBepridil may increase the hypotensive activities of Rescinnamine.
BetaxololBetaxolol may increase the hypotensive activities of Rescinnamine.
BethanidineBethanidine may increase the hypotensive activities of Rescinnamine.
BimatoprostBimatoprost may increase the hypotensive activities of Rescinnamine.
BisoprololBisoprolol may increase the hypotensive activities of Rescinnamine.
BosentanBosentan may increase the hypotensive activities of Rescinnamine.
BretyliumBretylium may increase the hypotensive activities of Rescinnamine.
BrimonidineRescinnamine may increase the hypotensive activities of Brimonidine.
BrimonidineBrimonidine may increase the antihypertensive activities of Rescinnamine.
BromfenacThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Bromfenac.
BumetanideBumetanide may increase the hypotensive activities of Rescinnamine.
BupranololBupranolol may increase the hypotensive activities of Rescinnamine.
CanagliflozinCanagliflozin may increase the hyperkalemic activities of Rescinnamine.
CandesartanCandesartan may increase the hypotensive activities of Rescinnamine.
CandoxatrilCandoxatril may increase the hypotensive activities of Rescinnamine.
CaptoprilCaptopril may increase the hypotensive activities of Rescinnamine.
CaroxazoneCaroxazone may increase the hypotensive activities of Rescinnamine.
CarprofenThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Carprofen.
CarteololCarteolol may increase the hypotensive activities of Rescinnamine.
CarvedilolCarvedilol may increase the hypotensive activities of Rescinnamine.
CastanospermineThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Castanospermine.
CelecoxibThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Celecoxib.
CeliprololCeliprolol may increase the hypotensive activities of Rescinnamine.
CertoparinCertoparin may increase the hyperkalemic activities of Rescinnamine.
ChloroquineThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Chloroquine.
ChlorothiazideChlorothiazide may increase the hypotensive activities of Rescinnamine.
ChlorthalidoneChlorthalidone may increase the hypotensive activities of Rescinnamine.
CilazaprilCilazapril may increase the hypotensive activities of Rescinnamine.
CiprofloxacinRescinnamine may increase the arrhythmogenic activities of Ciprofloxacin.
ClonidineClonidine may increase the hypotensive activities of Rescinnamine.
ClonixinThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Clonixin.
CryptenamineCryptenamine may increase the hypotensive activities of Rescinnamine.
CyclothiazideCyclothiazide may increase the hypotensive activities of Rescinnamine.
D-LimoneneThe risk or severity of adverse effects can be increased when Rescinnamine is combined with D-Limonene.
DalteparinDalteparin may increase the hyperkalemic activities of Rescinnamine.
DapoxetineDapoxetine may increase the orthostatic hypotensive activities of Rescinnamine.
DebrisoquinDebrisoquin may increase the hypotensive activities of Rescinnamine.
DeserpidineDeserpidine may increase the hypotensive activities of Rescinnamine.
DiazoxideDiazoxide may increase the hypotensive activities of Rescinnamine.
DiclofenacThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Diclofenac.
DiflunisalThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Diflunisal.
DiflunisalDiflunisal may decrease the antihypertensive activities of Rescinnamine.
DiltiazemDiltiazem may increase the hypotensive activities of Rescinnamine.
DorzolamideDorzolamide may increase the hypotensive activities of Rescinnamine.
DoxazosinDoxazosin may increase the hypotensive activities of Rescinnamine.
DrospirenoneRescinnamine may increase the hyperkalemic activities of Drospirenone.
DroxicamThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Droxicam.
EfonidipineEfonidipine may increase the hypotensive activities of Rescinnamine.
EnalaprilEnalapril may increase the hypotensive activities of Rescinnamine.
EnalaprilatEnalaprilat may increase the hypotensive activities of Rescinnamine.
EnoxaparinEnoxaparin may increase the hyperkalemic activities of Rescinnamine.
EpirizoleThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Epirizole.
EplerenoneEplerenone may increase the hyperkalemic activities of Rescinnamine.
EpoprostenolEpoprostenol may increase the hypotensive activities of Rescinnamine.
EprosartanEprosartan may increase the hypotensive activities of Rescinnamine.
Etacrynic acidEtacrynic acid may increase the hypotensive activities of Rescinnamine.
EtanerceptThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Etanercept.
EtodolacThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Etodolac.
EtofenamateThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Etofenamate.
EtoricoxibThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Etoricoxib.
Evening primrose oilThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Evening primrose oil.
EverolimusThe risk or severity of adverse effects can be increased when Everolimus is combined with Rescinnamine.
exisulindThe risk or severity of adverse effects can be increased when Rescinnamine is combined with exisulind.
FelodipineFelodipine may increase the hypotensive activities of Rescinnamine.
FenbufenThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Fenbufen.
FenoldopamFenoldopam may increase the hypotensive activities of Rescinnamine.
FenoprofenThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Fenoprofen.
FloctafenineThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Floctafenine.
FlunixinThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Flunixin.
FlurbiprofenThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Flurbiprofen.
ForasartanThe risk or severity of adverse effects can be increased when Forasartan is combined with Rescinnamine.
FosinoprilFosinopril may increase the hypotensive activities of Rescinnamine.
FurazolidoneFurazolidone may increase the hypotensive activities of Rescinnamine.
FurosemideFurosemide may increase the hypotensive activities of Rescinnamine.
GuanabenzGuanabenz may increase the hypotensive activities of Rescinnamine.
GuanadrelGuanadrel may increase the hypotensive activities of Rescinnamine.
GuanethidineGuanethidine may increase the hypotensive activities of Rescinnamine.
GuanfacineGuanfacine may increase the hypotensive activities of Rescinnamine.
HeparinHeparin may increase the hyperkalemic activities of Rescinnamine.
HexamethoniumHexamethonium may increase the hypotensive activities of Rescinnamine.
HMPL-004The risk or severity of adverse effects can be increased when Rescinnamine is combined with HMPL-004.
HydracarbazineHydracarbazine may increase the hypotensive activities of Rescinnamine.
HydralazineHydralazine may increase the hypotensive activities of Rescinnamine.
HydrochlorothiazideHydrochlorothiazide may increase the hypotensive activities of Rescinnamine.
HydroflumethiazideHydroflumethiazide may increase the hypotensive activities of Rescinnamine.
IbuprofenThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Ibuprofen.
IbuproxamThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Ibuproxam.
IcatibantIcatibant may decrease the antihypertensive activities of Rescinnamine.
IcatibantThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Icatibant.
IloprostIloprost may increase the hypotensive activities of Rescinnamine.
IndapamideIndapamide may increase the hypotensive activities of Rescinnamine.
IndenololIndenolol may increase the hypotensive activities of Rescinnamine.
IndomethacinThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Indomethacin.
IndoprofenThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Indoprofen.
IndoraminIndoramin may increase the hypotensive activities of Rescinnamine.
IproclozideIproclozide may increase the hypotensive activities of Rescinnamine.
IproniazidIproniazid may increase the hypotensive activities of Rescinnamine.
IrbesartanIrbesartan may increase the hypotensive activities of Rescinnamine.
IronThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Iron.
Iron DextranThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Iron Dextran.
IsocarboxazidIsocarboxazid may increase the hypotensive activities of Rescinnamine.
IsoxicamThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Isoxicam.
IsradipineIsradipine may increase the hypotensive activities of Rescinnamine.
KebuzoneThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Kebuzone.
KetoprofenThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Ketoprofen.
KetorolacThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Ketorolac.
LabetalolLabetalol may increase the hypotensive activities of Rescinnamine.
LacidipineLacidipine may increase the hypotensive activities of Rescinnamine.
Lanthanum carbonateThe serum concentration of Rescinnamine can be decreased when it is combined with Lanthanum carbonate.
LatanoprostLatanoprost may increase the hypotensive activities of Rescinnamine.
LeflunomideThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Leflunomide.
LercanidipineLercanidipine may increase the hypotensive activities of Rescinnamine.
LinagliptinThe risk or severity of adverse effects can be increased when Linagliptin is combined with Rescinnamine.
LisinoprilLisinopril may increase the hypotensive activities of Rescinnamine.
LithiumThe serum concentration of Lithium can be increased when it is combined with Rescinnamine.
LofexidineLofexidine may increase the hypotensive activities of Rescinnamine.
LornoxicamThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Lornoxicam.
LosartanLosartan may increase the hypotensive activities of Rescinnamine.
LoxoprofenThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Loxoprofen.
LumiracoxibThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Lumiracoxib.
MacitentanRescinnamine may increase the hypotensive activities of Macitentan.
Magnesium salicylateThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Magnesium salicylate.
ManidipineManidipine may increase the hypotensive activities of Rescinnamine.
MasoprocolThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Masoprocol.
MebanazineMebanazine may increase the hypotensive activities of Rescinnamine.
MecamylamineMecamylamine may increase the hypotensive activities of Rescinnamine.
Meclofenamic acidThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Meclofenamic acid.
Mefenamic acidThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Mefenamic acid.
MeloxicamThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Meloxicam.
MesalazineThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Mesalazine.
MesalazineMesalazine may decrease the antihypertensive activities of Rescinnamine.
MetamizoleThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Metamizole.
MethyclothiazideMethyclothiazide may increase the hypotensive activities of Rescinnamine.
MethyldopaMethyldopa may increase the hypotensive activities of Rescinnamine.
Methylene blueMethylene blue may increase the hypotensive activities of Rescinnamine.
MethylphenidateMethylphenidate may decrease the antihypertensive activities of Rescinnamine.
MetipranololMetipranolol may increase the hypotensive activities of Rescinnamine.
MetolazoneMetolazone may increase the hypotensive activities of Rescinnamine.
MetoprololMetoprolol may increase the hypotensive activities of Rescinnamine.
MibefradilMibefradil may increase the hypotensive activities of Rescinnamine.
MinaprineMinaprine may increase the hypotensive activities of Rescinnamine.
MinoxidilMinoxidil may increase the hypotensive activities of Rescinnamine.
MoclobemideMoclobemide may increase the hypotensive activities of Rescinnamine.
MoexiprilMoexipril may increase the hypotensive activities of Rescinnamine.
MolsidomineMolsidomine may increase the hypotensive activities of Rescinnamine.
MoxonidineMoxonidine may increase the hypotensive activities of Rescinnamine.
Mycophenolate mofetilThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Mycophenolate mofetil.
Mycophenolic acidThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Mycophenolic acid.
NabumetoneThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Nabumetone.
NadololNadolol may increase the hypotensive activities of Rescinnamine.
NadroparinNadroparin may increase the hyperkalemic activities of Rescinnamine.
NaftifineThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Naftifine.
NaproxenThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Naproxen.
NCX 4016The risk or severity of adverse effects can be increased when Rescinnamine is combined with NCX 4016.
NebivololNebivolol may increase the hypotensive activities of Rescinnamine.
NepafenacThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Nepafenac.
NialamideNialamide may increase the hypotensive activities of Rescinnamine.
NicardipineNicardipine may increase the hypotensive activities of Rescinnamine.
NicorandilNicorandil may increase the hyperkalemic activities of Rescinnamine.
NicorandilRescinnamine may increase the hypotensive activities of Nicorandil.
Niflumic AcidThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Niflumic Acid.
NiguldipineNiguldipine may increase the hypotensive activities of Rescinnamine.
NilvadipineNilvadipine may increase the hypotensive activities of Rescinnamine.
NimesulideThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Nimesulide.
NimodipineNimodipine may increase the hypotensive activities of Rescinnamine.
NisoldipineNisoldipine may increase the hypotensive activities of Rescinnamine.
NitrendipineNitrendipine may increase the hypotensive activities of Rescinnamine.
NitroprussideNitroprusside may increase the hypotensive activities of Rescinnamine.
ObinutuzumabRescinnamine may increase the hypotensive activities of Obinutuzumab.
OctamoxinOctamoxin may increase the hypotensive activities of Rescinnamine.
OlmesartanOlmesartan may increase the hypotensive activities of Rescinnamine.
OlopatadineThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Olopatadine.
OlsalazineThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Olsalazine.
OmapatrilatOmapatrilat may increase the hypotensive activities of Rescinnamine.
OrgoteinThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Orgotein.
OxaprozinThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Oxaprozin.
OxprenololOxprenolol may increase the hypotensive activities of Rescinnamine.
OxyphenbutazoneThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Oxyphenbutazone.
ParecoxibThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Parecoxib.
PargylinePargyline may increase the hypotensive activities of Rescinnamine.
ParnaparinParnaparin may increase the hyperkalemic activities of Rescinnamine.
PenbutololPenbutolol may increase the hypotensive activities of Rescinnamine.
PentoliniumPentolinium may increase the hypotensive activities of Rescinnamine.
PentoxifyllinePentoxifylline may increase the hypotensive activities of Rescinnamine.
PerindoprilPerindopril may increase the hypotensive activities of Rescinnamine.
PhenelzinePhenelzine may increase the hypotensive activities of Rescinnamine.
PheniprazinePheniprazine may increase the hypotensive activities of Rescinnamine.
PhenoxybenzaminePhenoxybenzamine may increase the hypotensive activities of Rescinnamine.
PhenoxypropazinePhenoxypropazine may increase the hypotensive activities of Rescinnamine.
PhentolaminePhentolamine may increase the hypotensive activities of Rescinnamine.
PhenylbutazoneThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Phenylbutazone.
PimecrolimusThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Pimecrolimus.
PinacidilPinacidil may increase the hypotensive activities of Rescinnamine.
PindololPindolol may increase the hypotensive activities of Rescinnamine.
PiretanidePiretanide may increase the hypotensive activities of Rescinnamine.
PirfenidoneThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Pirfenidone.
PirlindolePirlindole may increase the hypotensive activities of Rescinnamine.
PiroxicamThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Piroxicam.
PivhydrazinePivhydrazine may increase the hypotensive activities of Rescinnamine.
PolythiazidePolythiazide may increase the hypotensive activities of Rescinnamine.
PrazosinPrazosin may increase the hypotensive activities of Rescinnamine.
PregabalinThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Pregabalin.
PropacetamolThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Propacetamol.
PropranololPropranolol may increase the hypotensive activities of Rescinnamine.
PTC299The risk or severity of adverse effects can be increased when Rescinnamine is combined with PTC299.
QuinaprilQuinapril may increase the hypotensive activities of Rescinnamine.
QuinethazoneQuinethazone may increase the hypotensive activities of Rescinnamine.
QuinineQuinine may increase the hypotensive activities of Rescinnamine.
RamiprilRamipril may increase the hypotensive activities of Rescinnamine.
RasagilineRasagiline may increase the hypotensive activities of Rescinnamine.
RemikirenRemikiren may increase the hypotensive activities of Rescinnamine.
ReserpineReserpine may increase the hypotensive activities of Rescinnamine.
ResveratrolThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Resveratrol.
ReviparinReviparin may increase the hyperkalemic activities of Rescinnamine.
RiociguatRescinnamine may increase the hypotensive activities of Riociguat.
RituximabRescinnamine may increase the hypotensive activities of Rituximab.
RofecoxibThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Rofecoxib.
SacubitrilThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Sacubitril.
SafrazineSafrazine may increase the hypotensive activities of Rescinnamine.
SalicylamideThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Salicylamide.
Salicylic acidThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Salicylic acid.
Salicylic acidSalicylic acid may decrease the antihypertensive activities of Rescinnamine.
SalsalateThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Salsalate.
SaprisartanSaprisartan may increase the hypotensive activities of Rescinnamine.
SaralasinThe risk or severity of adverse effects can be increased when Saralasin is combined with Rescinnamine.
SaxagliptinThe risk or severity of adverse effects can be increased when Saxagliptin is combined with Rescinnamine.
SelegilineSelegiline may increase the hypotensive activities of Rescinnamine.
SelexipagSelexipag may increase the hypotensive activities of Rescinnamine.
SeratrodastThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Seratrodast.
SildenafilSildenafil may increase the antihypertensive activities of Rescinnamine.
SirolimusThe risk or severity of adverse effects can be increased when Sirolimus is combined with Rescinnamine.
SitagliptinThe risk or severity of adverse effects can be increased when Sitagliptin is combined with Rescinnamine.
SitaxentanRescinnamine may increase the hypotensive activities of Sitaxentan.
Sodium aurothiomalateThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Sodium aurothiomalate.
SpiraprilSpirapril may increase the hypotensive activities of Rescinnamine.
SpironolactoneSpironolactone may increase the hyperkalemic activities of Rescinnamine.
SRT501The risk or severity of adverse effects can be increased when Rescinnamine is combined with SRT501.
SulfasalazineThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Sulfasalazine.
SulindacThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Sulindac.
SuprofenThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Suprofen.
TadalafilTadalafil may increase the antihypertensive activities of Rescinnamine.
TasosartanThe risk or severity of adverse effects can be increased when Tasosartan is combined with Rescinnamine.
TelmisartanTelmisartan may increase the hypotensive activities of Rescinnamine.
TemocaprilTemocapril may increase the hypotensive activities of Rescinnamine.
TemsirolimusThe risk or severity of adverse effects can be increased when Temsirolimus is combined with Rescinnamine.
TenoxicamThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Tenoxicam.
TepoxalinThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Tepoxalin.
TeriflunomideThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Teriflunomide.
TerlipressinTerlipressin may increase the hypotensive activities of Rescinnamine.
Tiaprofenic acidThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Tiaprofenic acid.
TiboloneTibolone may increase the hypotensive activities of Rescinnamine.
TicrynafenTicrynafen may increase the hypotensive activities of Rescinnamine.
TimololTimolol may increase the hypotensive activities of Rescinnamine.
TinzaparinTinzaparin may increase the hyperkalemic activities of Rescinnamine.
TizanidineTizanidine may increase the hypotensive activities of Rescinnamine.
TolazolineTolazoline may increase the hypotensive activities of Rescinnamine.
Tolfenamic AcidThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Tolfenamic Acid.
TolmetinThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Tolmetin.
ToloxatoneToloxatone may increase the hypotensive activities of Rescinnamine.
TolvaptanTolvaptan may increase the hyperkalemic activities of Rescinnamine.
TorasemideTorasemide may increase the hypotensive activities of Rescinnamine.
TrandolaprilTrandolapril may increase the hypotensive activities of Rescinnamine.
TranilastThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Tranilast.
Trans-2-PhenylcyclopropylamineTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Rescinnamine.
TranylcypromineTranylcypromine may increase the hypotensive activities of Rescinnamine.
TravoprostTravoprost may increase the hypotensive activities of Rescinnamine.
TreprostinilTreprostinil may increase the hypotensive activities of Rescinnamine.
TriamtereneTriamterene may increase the hyperkalemic activities of Rescinnamine.
TrichlormethiazideTrichlormethiazide may increase the hypotensive activities of Rescinnamine.
TrimazosinTrimazosin may increase the hypotensive activities of Rescinnamine.
TrimethaphanTrimethaphan may increase the hypotensive activities of Rescinnamine.
TrimethoprimTrimethoprim may increase the hyperkalemic activities of Rescinnamine.
Trisalicylate-cholineThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Trisalicylate-choline.
UdenafilUdenafil may increase the antihypertensive activities of Rescinnamine.
UnoprostoneUnoprostone may increase the hypotensive activities of Rescinnamine.
ValdecoxibThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Valdecoxib.
ValsartanValsartan may increase the hypotensive activities of Rescinnamine.
VardenafilVardenafil may increase the antihypertensive activities of Rescinnamine.
VildagliptinThe risk or severity of adverse effects can be increased when Vildagliptin is combined with Rescinnamine.
XylometazolineXylometazoline may increase the hypotensive activities of Rescinnamine.
YohimbineYohimbine may decrease the antihypertensive activities of Rescinnamine.
ZaltoprofenThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Zaltoprofen.
ZileutonThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Zileuton.
ZomepiracThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Zomepirac.
Food InteractionsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Zinc ion binding
Specific Function:
Converts angiotensin I to angiotensin II by release of the terminal His-Leu, this results in an increase of the vasoconstrictor activity of angiotensin. Also able to inactivate bradykinin, a potent vasodilator. Has also a glycosidase activity which releases GPI-anchored proteins from the membrane by cleaving the mannose linkage in the GPI moiety.
Gene Name:
ACE
Uniprot ID:
P12821
Molecular Weight:
149713.675 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  3. Azhar I, Mazhar F, Manzar QN, Hussain I, Shamim S: Colorimetric determination of indolic drugs. Pak J Pharm Sci. 2005 Apr;18(2):48-51. [PubMed:16431399 ]
  4. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23